Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn’s Disease: Results of a Decision Analysis

Author： Ananthakrishnan Ashwin   Hur Chin   Korzenik Joshua  

Publisher： Springer Publishing Company

ISSN： 0163-2116

Source： Digestive Diseases and Sciences, Vol.57, Iss.2, 2012-02, pp. : 472-480

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mild-to-Moderate Active Luminal Crohn’s Disease

By  

Digestion, Vol. 76, Iss. 2, 2008-02 ,pp. : 92-98

Karger

Access to resources Recommend Favorite

Therapy of Mild to Moderate Luminal Crohn’s Disease

By  

Digestion, Vol. 71, Iss. 1, 2005-03 ,pp. : 13-18

Karger

Access to resources Recommend Favorite

Severe and Steroid-Resistant Crohn’s Disease

By  

Digestion, Vol. 76, Iss. 2, 2008-02 ,pp. : 99-108

Karger

Access to resources Recommend Favorite

Severe and Steroid-Resistant Crohn’s Disease

By  

Digestion, Vol. 71, Iss. 1, 2005-03 ,pp. : 19-25

Karger

Access to resources Recommend Favorite

Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey

By  

Digestive Diseases, Vol. 35, Iss. 5, 2017-06 ,pp. : 423-432

Karger

Access to resources Recommend Favorite